WESTLAKE VILLAGE, Calif., July 26, 2017 (GLOBE NEWSWIRE) — Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the pricing of the Company’s initial public offering of 4,333,333 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares of common stock are being offered by Sienna. The Company has also granted the underwriters a 30-day option to purchase from the Company an additional 650,000 shares of common stock at the initial public offering price, less the underwriting discount. Sienna’s common stock has been approved for listing on The NASDAQ Global Select Market and is expected to begin trading under the ticker symbol “SNNA” on July 27, 2017. The offering is expected to close on Aug. 1, 2017, subject to customary closing conditions.
J.P. Morgan and Cowen are acting as joint book-running managers for the proposed offering. BMO Capital Markets is also acting as bookrunner for the proposed offering.
A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on July 26, 2017. The offering of these shares will be made only by means of a prospectus. Copies of the prospectus may be obtained from J.P. Morgan, by mail at J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; from Cowen, by mail at Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at (631) 274-2806; or from BMO Capital Markets, by mail at BMO Capital Markets Corp., c/o 3 Times Square, 25th Floor, New York, NY 10036, Attention: Syndicate Department, or by telephone at (800) 414-3627.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. Sienna’s objective is to develop an innovative, diversified, multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology and aesthetics patients. Sienna is led by a management team with extensive experience in product development and commercialization at several leading dermatology, aesthetics and biotechnology companies.